The News

Movetis launches Resolor® in Germany

27/01/2010

First market introduction of Movetis lead medicine

Turnhout (Belgium), 27 January 2010 (7:30 AM CET) – Movetis, a European pharmaceutical company focused on the discovery, development and commercialisation of innovative drugs for the treatment of diseases in the GI area, announces that it has launched its lead product, Resolor® (prucalopride) in Germany. As of today, pharmacists in Germany can dispense Resolor to patients who have received a medical prescription for this medicine.

On 15 October 2009 Movetis obtained approval for the commercialisation of Resolor in the European Economic Area for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Prucalopide is the first molecule from the Movetis portfolio that has been developed into a marketed medicinal product.

Resolor, which is a once a day oral product, is available in 1mg and 2mg tablets in packs each containing 28 tablets. In German pharmacies Resolor will be sold at a public price, including VAT, of €61.65 for the 1mg pack and €89.68 for the 2mg pack. Given the fact that Resolor is a prescription-only medicine for the treatment of a serious chronic indication for which other available therapies do not provide adequate relief, the product meets the criteria for reimbursement in Germany.

Movetis has recently set up its own commercial organisation in Germany and has also concluded an alliance with Quintiles which has made a team of medical representatives available to support Resolor in Germany, and later in other selected European countries. This team started the process of informing the medical community in Germany about Resolor earlier this month. A key priority for the German sales team is to contact specialised gastroenterologists.

German physicians and pharmacists can as of this week also find more detailed scientific information about the product on a special section with restricted access on the Company’s German website.

Pieter Korst, Vice-President Marketing and Customer Relationship Management at Movetis commented: “With the supply to the German pharmaceutical distribution network now in place, patients can rely on swift access to Resolor.”

Dirk Reyn, Chief Executive Officer of Movetis added: “The launch of Resolor in Germany is yet another important milestone in the relatively short history of Movetis. The market introduction in Germany was scheduled for the first quarter of 2010, and we have clearly achieved this objective. Every day we receive more and more questions from physicians, illustrating there is a clear interest for a product such as Resolor.”

In this context, Movetis has set up a collaboration with the UK-based company IDIS in order to provide pre-launch access to Resolor in those countries where the product already has received marketing approval but where the pricing and reimbursement procedures are still running, and where this is allowed by national regulations. Doctors and pharmacists can contact IDIS for more information (www.idispharma.com).

Movetis is preparing the commercial launch of Resolor in the UK for the second quarter of 2010. Pricing and reimbursement procedures are progressing as scheduled. Taking account of applicable VAT rates, national price structures and currency exchange rates, the public prices of Resolor in the UK and Germany are situated at a comparable level.

About Movetis
Movetis is a European specialty GI company that is focused on improving the lives of millions of patients – both adults and children – by discovering, developing and commercialising innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson.

Movetis has a broad portfolio of GI products: Resolor® (prucalopride) is approved in the EEA for the indication “symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief” and the marketing authorisation application is furthermore under review in Switzerland; two products are in Phase II development and Movetis has two prioritised compounds in preclinical development, all addressing important GI areas including ascites, paediatric reflux, refractory GORD (gastroesophageal reflux disease) and severe forms of irritable bowel syndrome.

In addition, Movetis has rights to a large library of qualified lead compounds with potential for development in different GI indications and access to know how for compounds in secretory diarrhoea. The current portfolio is licensed from Janssen Pharmaceutica NV, Belgium and Ortho-McNeil Pharmaceutical Inc., two Johnson & Johnson companies. Movetis shares are listed on Euronext Brussels under the ticker MOVE.

For further inquiries, please contact:
Movetis
Ingrid Jansen Chris Van Raemdonck
+3214404390 +32499585531
Email Email
Citigate Dewe Rogerson
David Dible/Chris Gardner/Amber Bielecka
+44 (0) 207 638 9571
Email

Disclaimer: This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Movetis, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward looking statements. These forward-looking statements speak only as of the date of publication of this document. Movetis expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change  n its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.